医学
贝伐单抗
拓扑替康
宫颈癌
化疗
危险系数
紫杉醇
内科学
肿瘤科
顺铂
外科
泌尿科
癌症
置信区间
作者
Krishnansu S. Tewari,Michael W. Sill,Harry J. Long,Richard T. Penson,Helen Huang,Lois M. Ramondetta,Lisa M. Landrum,Ana Oaknin,Thomas Reid,Mario M. Leitão,Helen E. Michael,Bradley J. Monk
标识
DOI：10.1056/nejmoa1309748
摘要
The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival. (Funded by the National Cancer Institute; GOG 240 ClinicalTrials.gov number, NCT00803062.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Criminology34
Tanya47
熬夜波比
Nature
遇上就这样吧
寻道图强
无极微光
MchemG
556
殷勤的紫槐
Yini
GingerF
YifanWang
yznfly
优美的小笨蛋
大龙哥886
从容芮
22222
andrele
美好斓
ZHL
Twonej
sxb10101
dawnfrf
皖公网安备34019202002308
